deltatrials
Completed PHASE2 NCT00004393

Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome

Sponsor: National Center for Research Resources (NCRR)

Conditions Tourette Syndrome
Interventions risperidone
Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Jul 31, 1997 Completion: Sep 30, 2000

A PHASE2 clinical study on Tourette Syndrome, this trial is completed. The trial is conducted by National Center for Research Resources (NCRR) and has accumulated 5 data snapshots since 1997. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Center for Research Resources (NCRR)
  • Yale University
Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.